NEW YORK (GenomeWeb News) – The Genetics and Public Policy Center at Johns Hopkins University said this week that drug maker Eli Lilly has provided the center with $110,000 to study currently regulatory processes for pharmacogenetic drugs and devices.
According to GPPC, the study also will identify impediments to pharmacogenetic innovation and adoption by healthcare providers. It also will propose regulatory reforms.
The center made the announcement in its monthly newsletter. It said that the grant period began on Oct. 1, and it will run for one year.
GPPC plans to conduct case studies for cancer, sepsis, and neuroscience drugs and interview officials from the US Food and Drug Administration and industry to investigate the regulatory barriers to the development and adoption of pharmacogenetic products. The center anticipates that its findings will aid policy makers in developing policies that will foster pharmacogenetic innovation.
The primary audience for the project is policy makers within the Department of Health and Human Services and Congress, and GPPC believes its findings will be useful for the pharmaceutical and medical device industries.
Last month, GPPC received a $600,000 grant from the National Human Genome Research Institute to study the new direct-to-consumer genetic testing industry.